Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - Analysis by Product, Surgery, End User and Region

The global electrosurgery market is projected to grow from $8.01 billion in 2025 to $11.59 billion by 2031, with a CAGR of 6.4%. Growth is driven by increasing surgical volumes, rising chronic disease prevalence, and adoption of minimally invasive procedures. However, challenges include procedural risks, regulatory constraints, and surgeon shortages. Ambulatory surgical centers are expanding their role, while the United States leads North American growth.

07/24/2026, 10:41 AM • GlobeNewswire

This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It

Johnson & Johnson is transitioning from a slow-growth dividend stock into a growth machine, driven primarily by its oncology business. The company's cancer drugs, particularly Darzalex, are growing at high-teen rates, positioning J&J to achieve its goal of $50 billion in annual cancer drug sales by 2030. With the global cancer treatment market expected to grow at 11.3% annually through 2035, J&J is well-positioned to capture significant market share despite being primarily viewed as an income investment.

07/24/2026, 10:15 AM • The Motley Fool

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.

07/24/2026, 12:30 AM • The Motley Fool

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) with 110 holdings offering global diversification and lower volatility, versus VanEck Biotech ETF (BBH) with 25 concentrated biotech positions delivering higher short-term returns but greater drawdown risk. IXJ is recommended for its superior long-term performance, geographic diversity, and stability despite BBH's impressive 30.8% one-year return.

07/23/2026, 3:30 PM • The Motley Fool

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

First Trust NYSE Arca Biotechnology Index Fund (FBT) offers concentrated exposure to 30 biotech stocks with 51.6% 1-year returns but higher volatility and a 0.55% expense ratio. Vanguard Health Care ETF (VHT) provides broader diversification across 400+ healthcare companies with lower costs (0.09% expense ratio) and dividend yield, making it better for long-term stability. FBT suits investors with high risk tolerance and biotech conviction, while VHT is recommended for those seeking healthcare as a portfolio stabilizer.

07/23/2026, 8:15 AM • The Motley Fool

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.

07/22/2026, 4:33 PM • The Motley Fool

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and Invesco Pharmaceuticals ETF (PJP). VHT offers broader sector exposure with 411 holdings, a lower expense ratio of 0.09%, and higher dividend yield of 1.60%. PJP focuses narrowly on 29 pharmaceutical stocks with a 0.57% expense ratio and 0.90% yield. Despite VHT's cost advantages, PJP has significantly outperformed over 3 and 5-year periods (17.3% and 9.1% returns respectively), leading the author to recommend PJP as the better buy for 2026.

07/22/2026, 3:13 PM • The Motley Fool

Global Robotic Endoscopy Devices Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~10% by 2034 | DelveInsight

The global robotic endoscopy devices market is projected to grow from USD 2.8 billion in 2025 to USD 6.5 billion by 2034, driven by increasing demand for minimally invasive procedures, technological advancements in AI-enabled navigation and imaging, and rising prevalence of gastrointestinal disorders. North America leads the market with 42% share, while Asia-Pacific is expected to witness the highest growth. Key players include Intuitive Surgical, Medtronic, Johnson & Johnson MedTech, and others.

07/22/2026, 1:00 PM • GlobeNewswire

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

iShares Global Healthcare ETF (IXJ) offers broad diversification across 110 global healthcare companies with a lower 0.40% expense ratio, while First Trust NYSE Arca Biotechnology Index Fund (FBT) concentrates on 30 biotech companies with higher growth potential but greater volatility. IXJ suits defensive investors seeking stable exposure to established pharma giants, while FBT appeals to those betting on biotech breakthroughs despite higher risk.

07/21/2026, 2:12 PM • The Motley Fool

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

IXJ and RSPH are two healthcare ETFs with different strategies: IXJ uses cap-weighted global exposure with larger pharmaceutical companies, offering higher dividends (1.47%) and lower volatility (beta 0.52), while RSPH employs equal-weighting of S&P 500 healthcare stocks, providing stronger 1-year returns (21.01% vs 18.29%) but higher risk (beta 0.81). The choice depends on investor goals—IXJ suits conservative/income-focused investors, while RSPH appeals to growth-oriented investors willing to accept volatility.

07/21/2026, 1:32 PM • The Motley Fool

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma announced completion of enrollment in its Phase 3 APPROACH pivotal study of HLP003, an investigational treatment for major depressive disorder, ahead of schedule. The study enrolled 223 participants with moderate to severe MDD who showed inadequate response to standard antidepressants. Topline data is expected in Q4 2026, with potential FDA New Drug Application submission targeted for 2028. The company also noted strong market demand for novel depression treatments, citing Johnson & Johnson's SPRAVATO sales growth.

07/21/2026, 7:50 AM • GlobeNewswire

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?

Eli Lilly's stock has surged above $1,000, driven primarily by its dominant position in the weight loss drug market. With the stock trading at these elevated levels, analysts speculate whether the company might announce a stock split to make shares more accessible to investors. While Lilly hasn't executed a stock split since 1997, a move could broaden its investor base and signal management confidence in future growth, particularly given recent launches like Foundayo and strong trial results for retatrutide.

07/20/2026, 2:10 PM • The Motley Fool

Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?

The article compares two healthcare ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on concentrated U.S. pharma exposure with 29 holdings, and iShares Global Healthcare ETF (IXJ), which offers diversified global healthcare with 110 holdings. PJP delivered superior 1-year returns of 44.90% versus IXJ's 18.20%, though IXJ has a lower expense ratio (0.40% vs 0.57%) and higher dividend yield (1.50% vs 0.90%). The article recommends PJP for investors seeking healthcare exposure due to its stronger performance across most timeframes.

07/20/2026, 10:17 AM • The Motley Fool

Urology Devices Market Size to Reach USD 80.0 Billion by 2035 | SNS Insider

The global urology devices market is valued at USD 39.23 billion in 2025 and is projected to reach USD 80.0 billion by 2035, growing at a CAGR of 7.35%. Growth is driven by rising demand for robotic-assisted surgery, kidney disease treatment, and minimally invasive procedures. North America leads the market while Asia Pacific records the fastest growth.

07/20/2026, 7:53 AM • GlobeNewswire